<DOC>
	<DOCNO>NCT02065336</DOCNO>
	<brief_summary>The purpose study determine whether ARC-520 combination entecavir effective treatment patient Chronic Hepatitis B Virus ( HBV ) Infection .</brief_summary>
	<brief_title>Study ARC-520 Patients With Chronic Hepatitis B Virus</brief_title>
	<detailed_description>Treatment ARC-520 injection expect reduce HBV protein replicative intermediate via RNA interference . The magnitude reduction duration effect depend dose . Since date ARC-520 administer patient chronic HBV infection , effective therapeutic dose patient chronic HBV infection unknown . This study design assess antiviral activity ARC-520 , especially 's effect HBsAg , patient chronic HBV infection different dose level . This multicenter , randomize , double-blind , placebo-controlled , single dose escalation study ARC 520 combination entecavir administer patient HBeAg negative ( Cohorts 1 4 ) HBeAg positive ( Cohort 5 ) immune active , chronic HBV infection , follow two-dose open-label cohort ( Cohort 6 ) , three open label single dose cohort treatment naïve patient ( Cohorts 7 , 11 12 ) open label multi-dose extension study ( cohorts 8 , 9 , 10 ) . Cohort 6 investigate ARC-520 combination entecavir administer two dos patient HBeAg positive immune active chronic HBV infection . Cohorts 7 , 11 12 enroll treatment naïve patient . Cohort 8 enroll subject previously complete cohort 1-4 . Cohort 9 enroll subject previously complete cohort 5 6 . Cohort 10 enroll subject previously complete cohort 7 . Patients undergo following evaluation regular interval study : medical history , physical examination , vital sign measurement ( blood pressure , heart rate , respiratory rate , temperature ) , weight , adverse event ( AEs ) , 12-lead electrocardiogram ( ECGs ) , concomitant medication , blood sample collection hematology , coagulation , chemistry , pharmacokinetic ( PK ) exploratory pharmacodynamic ( PD ) measure , urinalysis , HBV serology , HBV genotyping sequencing , FSH test pregnancy test female childbearing potential . Clinically significant change include AEs follow resolution , condition stabilizes , event otherwise explain , patient lose follow-up .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Key Diagnosis HBeAg negative immune active chronic HBV infection ( Cohorts 14 , 8 ) Diagnosis HBeAg positive immune active chronic HBV infection ( Cohorts 56 , 9 ) Diagnosis HBeAg negative HBeAg positive immune active tolerant chronic HBV infection ( Cohorts 7 , 10 , 11 &amp; 12 ) Patients &gt; 6 month continuous , 0.5 mg/day oral entecavir , willingness continue take entecavir throughout study ( Cohorts 16 , 89 ) . Patients naive entecavir ( never entecavir entecavir &lt; 30 day prior screen ) willingness take entecavir willingness continue take entecavir throughout study ( Cohorts 7 , 11 &amp; 12 ) . Key Female patient positive pregnancy test lactating . Acute sign hepatitis/other infection ( eg , moderate fever , jaundice , nausea , vomit , abdominal pain ) evident within 4 week screen and/or screen examination . Patients antiviral therapy entecavir within 3 month screen prior treatment interferon toll receptor agonist last 5 year . Use within last 6 month anticipate requirement anticoagulant , corticosteroid , immunomodulators , immunosuppressant . Has history autoimmune disease especially autoimmune hepatitis . Has human immunodeficiency virus ( HIV ) infection , show presence antiHIV antibody ( seropositive ) . Is seropositive hepatitis C virus ( HCV ) , and/or history delta virus hepatitis . Has history allergy bee venom history hypersensitivity reaction require emergency visit physician hospital and/or requirement treatment steroid and/or epinephrine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HBV</keyword>
	<keyword>Hepatitis</keyword>
</DOC>